At ONIRIA Therapeutics, we translate hard-won knowledge on cancer cell resistance to advanced treatments for patients. We have found that latent cells exist from the very beginning in primary tumors, later along undetectable residual disease phases and finally in recurrent tumors. These dormant cells are the long-term core of cancer persistence. But we have also discovered that tumor cell dormancy comes at a cost. While it enables the tumor to escape drug treatments, dormancy also exposes the cancer cells to unforeseen vulnerabilities. ONIRIA‘s novel strategy modulates the dormant state of cancer cells to exploit these vulnerabilities and overcome disease persistence, thereby prolonging patients‘ lives and ultimately cure them.